1-甲基-1,2,3,4-四氢-喹唑啉 | 103796-63-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 1-甲基-1,2,3,4-四氢-喹唑啉
• 英文名称: 1-methyl-1,2,3,4-tetrahydro-quinazoline
• 英文别名: 1-Methyl-1,2,3,4-tetrahydro-chinazolin；N-methyldihydroquinazoline；1-methyl-3,4-dihydro-2H-quinazoline
• CAS: 103796-63-0
• 化学式: C₉H₁₂N₂
• 分子量: 148.208
• InChiKey: BIVLCLLZFCYRPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-甲基喹唑啉-4-酮 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 1-甲基-1,2,3,4-四氢-喹唑啉
  参考文献：
  名称：

  Osborn; Schofield, Journal of the Chemical Society, 1956, p. 3977

  摘要：

  DOI：

文献信息

• Drug Resistance Reversal In Neoplastic Disease
  申请人：Patil Ghanshyam

  公开号：US20080200405A1

  公开（公告）日：2008-08-21

  The present invention is directed to compounds, compositions, and methods for halting or reversing the effects of chemoresistance in neoplastic diseases. In particular the use of hydroxylamines is described.

  本发明涉及用于阻止或逆转肿瘤性疾病化疗耐药效应的化合物、组合物和方法。具体描述了羟胺的使用。
• DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS
  申请人：Chiesi Farmaceutici S.p.A.

  公开号：US20130102576A1

  公开（公告）日：2013-04-25

  Compounds, pyridine N-oxides, and pharmaceutically acceptable salts of formula (I) are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and for preventing and/or treating diseases of the respiratory tract characterized by airway obstruction, such as asthma or COPD.

  化合物，吡啶N-氧化物和具有以下结构的药学上可接受的盐（I）的盐对于抑制磷酸二酯酶4（PDE4）酶并预防和/或治疗呼吸道疾病，其特征是气道阻塞，如哮喘或COPD，是有用的。
• Sulfamoyl benzamide derivatives and methods of their use
  申请人：Dolle E. Roland

  公开号：US20060079557A1

  公开（公告）日：2006-04-13

  Novel sulfamoyl benzamide compounds, pharmaceutical compositions containing the sulfamoyl benzamide compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the sulfamoyl benzamide compounds are agonists and/or modulating ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, inflammation, auto-immune diseases, ischemic conditions, immune-related disorders, hypertension, neurological disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, for inhibiting mechanical hyperalgesia associated with nerve injury, and as an appetite stimulant.

  新型磺胺基苯甲酰胺化合物，含有该磺胺基苯甲酰胺化合物的药物组合物，以及它们的药用方法被披露。在某些实施例中，磺胺基苯甲酰胺化合物是大麻素受体的激动剂和/或调节配体，可能有助于治疗和/或预防疼痛、胃肠道疾病、炎症、自身免疫疾病、缺血症状、免疫相关疾病、高血压、神经系统疾病和神经退行性疾病，提供心脏保护作用抵抗缺血和再灌注效应，诱导恶性细胞凋亡，抑制与神经损伤相关的机械性过敏，以及作为食欲刺激剂。
• Sulfamoyl Benzamides and Methods of Their Use
  申请人：Dolle E. Roland

  公开号：US20080058302A1

  公开（公告）日：2008-03-06

  Novel sulfamoyl benzamide compounds, pharmaceutical compositions containing the sulfamoyl benzamide compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the sulfamoyl benzamide compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, inflammation, auto-immune diseases, ischemic conditions, immune-related disorders, hypertension, neurological disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, for inhibiting mechanical hyperalgesia associated with nerve injury, and as an appetite stimulant.

  本发明涉及新型磺酰胺苯甲酰胺化合物、含有该磺酰胺苯甲酰胺化合物的制药组合物以及它们的制药用途的方法。在某些实施例中，该磺酰胺苯甲酰胺化合物是大麻素受体的激动剂和/或配体，可用于治疗和/或预防疼痛、胃肠障碍、炎症、自身免疫性疾病、缺血性疾病、免疫相关疾病、高血压、神经系统疾病和神经退行性疾病，提供对缺血和再灌注效应的心脏保护作用，诱导恶性细胞凋亡，抑制与神经损伤相关的机械性高痛敏，并作为食欲刺激剂。
• HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE
  申请人：Patil Ghanshyam

  公开号：US20080280890A1

  公开（公告）日：2008-11-13

  The present disclosure provides compounds that include hydroxylamines of formula I or II, pharmaceutical compositions, and methods for their use. The methods utilize hydroxylamine compounds and/or their pharmaceutical compositions for the treatment of angiogenesis, hepatitis, complement-mediated pathologies, drusen-mediated pathologies, macular degeneration and certain other ophthalmic conditions, inflammation, arthritis, and related diseases and for the inhibition of complement activation.

  本公开提供了包括式I或II的羟胺化合物、制药组合物以及它们的使用方法。该方法利用羟胺化合物及/或其制药组合物治疗血管生成、肝炎、补体介导的病理、色斑介导的病理、黄斑变性和某些其他眼科疾病、炎症、关节炎和相关疾病，并抑制补体激活。